ESC

This channel contains news about the European Society of Cardiology (ESC), including coverage of its annual meeting and new guidelines. ESC is a leading resource for cardiology science and information in Europe.

A small study has shown that SARS-CoV-2 vaccination in patients who had an inflamed heart muscle in the past is not associated with a recurrence of the condition or other serious side effects.

News | Coronavirus (COVID-19)

Study: COVID-19 Vaccination is Safe in Patients with Previous Myocarditis

March 22, 2022 — A small study has shown that SARS-CoV-2 vaccination in patients who had an inflamed heart muscle in the ...

March 22, 2022

Women are less likely to receive lifesaving treatment for cardiogenic shock than men, according to research presented today at ESC Acute CardioVascular Care 2022, a scientific congress of the European Society of Cardiology (ESC).

News | Cardiogenic Shock

Women More Likely to Die After Heart Emergency than Men

March 22, 2022 – Women are less likely to receive lifesaving treatment for cardiogenic shock than men, according to ...

March 22, 2022

Just 76% of heart attack patients with dyspnoea or fatigue as their main symptom are alive at one year compared to 94% of those with chest pain as the predominant feature. That’s the finding of research presented today at ESC Acute CardioVascular Care 2022, a scientific congress of the European Society of Cardiology (ESC)

News | Heart Failure

Shortness of Breath Heralds Worse Survival than Chest Pain for Heart Attack Patients

March 22, 2022 – Just 76% of heart attack patients with dyspnoea or fatigue as their main symptom are alive at one year ...

March 22, 2022

European Society of Cardiology (ESC) top news stories in 2021

News | ESC

Top 10 ESC Stories in the News in 2021

January 3, 2022 — The following is a list of the 2021 news stories from the European Society of Cardiology (ESC) release ...

January 03, 2022

$FDA Grants Empagliflozin Breakthrough Therapy Status for Heart Failure With Preserved Ejection Fraction. he U.S. Food and Drug Administration (FDA) recently granted the breakthrough therapy designation for empagliflozin (Jardiance) as an investigational treatment for adults with heart failure with preserved ejection fraction (HFpEF).$

News | Pharmaceuticals

FDA Grants Empagliflozin Breakthrough Therapy Status for Heart Failure With Preserved Ejection Fraction

October 7, 2021 – The U.S. Food and Drug Administration (FDA) recently granted the breakthrough therapy designation for ...

October 07, 2021

A comparison between healthy artery (left) and inflamed artery (right) using perivascular fat attenuation index (FAI) mapping to detect spatial changes in perivascular fat composition induced by inflammation of the vascular wall caused by high-risk plaques.

Feature | Computed Tomography (CT)

CT Coronary Perivascular Fat Assessment Can Stratify Cardiac Risk Associated With High-Risk Plaques

October 6, 2021 — Data presented during the late-breaking science session at the European Society of Cardiology (ESC) 20 ...

October 06, 2021

European Society of Cardiology 2021 Late-breaking hot-line Studies presented with links.

News | ESC | By Dave Fornell, DAIC Editor

European Society of Cardiology 2021 Late-breaking Studies

October 4, 2021 — Here are links to all the late-breaking cardiology studies presented in Hot-Line sessions at the 2021 ...

October 04, 2021

$A pooled analysis of two randomized trials has demonstrated the beneficial effects of empagliflozin in patients with heart failure with a reduced and preserved ejection fraction. The late breaking study is presented in a Hot Line at the European Society of Cardiology (ESC) 2021 Congress, and was published in the New England Journal of Medicine. Data from the EMPEROR-Preserved and in EMPEROR-Reduced trials.$